| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8443554 | European Journal of Cancer | 2014 | 10 Pages |
Abstract
The results suggest that cabazitaxel has a manageable safety profile in everyday clinical practice. Prophylactic use of G-CSF, especially at cycle 1 and in men aged ⩾75 years, is important and improves tolerability in senior adults treated with cabazitaxel.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Axel Heidenreich, Sergio Bracarda, Malcolm Mason, Haluk Ozen, Lisa Sengelov, Inge Van Oort, Christos Papandreou, Sophie Fossa, Simon Hitier, Miguel Angel Climent, European investigators European investigators,